ダウンロード数: 102
このアイテムのファイル:
ファイル | 記述 | サイズ | フォーマット | |
---|---|---|---|---|
cancers11121891.pdf | 3.1 MB | Adobe PDF | 見る/開く |
タイトル: | Microrna-9-5p-CDX2 axis: A useful prognostic biomarker for patients with stage II/III colorectal cancer |
著者: | Nishiuchi, Aya Hisamori, Shigeo https://orcid.org/0000-0003-0163-6978 (unconfirmed) Sakaguchi, Masazumi Fukuyama, Keita https://orcid.org/0000-0001-8176-6961 (unconfirmed) Hoshino, Nobuaki Itatani, Yoshiro https://orcid.org/0000-0001-7356-7065 (unconfirmed) Honma, Shusaku Maekawa, Hisatsugu Nishigori, Tatsuto Tsunoda, Shigeru Obama, Kazutaka https://orcid.org/0000-0003-2924-6701 (unconfirmed) Miyoshi, Hiroyuki Shimono, Yohei Mark Taketo, M. Sakai, Yoshiharu |
著者名の別形: | 久森, 重夫 福山, 啓太 板谷, 喜朗 錦織, 達人 角田, 茂 小濵, 和貴 三好, 弘之 武藤, 誠 坂井, 義治 |
キーワード: | CDX2 stage II/III colorectal cancer microRNA-9-5p |
発行日: | 1-Dec-2019 |
出版者: | MDPI AG |
誌名: | Cancers |
巻: | 11 |
号: | 12 |
論文番号: | 1891 |
抄録: | A lack of caudal-type homeobox transcription factor 2 (CDX2) protein expression has been proposed as a prognostic biomarker for colorectal cancer (CRC). However, the relationship between CDX2 levels and the survival of patients with stage II/III CRC along with the relationship between microRNAs (miRs) and CDX2 expression are unclear. Tissue samples were collected from patients with stage II/III CRC surgically treated at Kyoto University Hospital. CDX2 expression was semi-quantitatively evaluated by immunohistochemistry (IHC). The prognostic impacts of CDX2 expression on overall survival (OS) and relapse-free survival (RFS) were evaluated by multivariable statistical analysis. The expression of miRs regulating CDX2 expression and their prognostic impacts were analyzed using The Cancer Genome Atlas Program for CRC (TCGA-CRC). Eleven of 174 CRC tissues lacked CDX2 expression. The five-year OS and RFS rates of patients with CDX2-negative CRC were significantly lower than those of CDX2-positive patients. Multivariate analysis of clinicopathological features revealed that CDX2-negative status is an independent marker of poor prognosis in stage II/III CRC. miR-9-5p was shown to regulate CDX2 expression. TCGA-CRC analysis showed that high miR-9-5p expression was significantly associated with poor patient prognosis in stage II/III CRC. In conclusion, CDX2, the post-transcriptional target of microRNA-9-5p, is a useful prognostic biomarker in patients with stage II/III CRC. |
著作権等: | © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
URI: | http://hdl.handle.net/2433/250985 |
DOI(出版社版): | 10.3390/cancers11121891 |
PubMed ID: | 31783700 |
出現コレクション: | 学術雑誌掲載論文等 |
このリポジトリに保管されているアイテムはすべて著作権により保護されています。